Prescription sleep aids are used far more widely than many people expect, with 2020 market value at $80.5 billion projected to reach $115.2 billion by 2028. Yet the benefits and risks swing sharply across drugs and outcomes, from a 19 minute average reduction in sleep onset time with zolpidem to links with hip fractures, dementia risk, driving impairment, and higher mortality.
Key Takeaways
- Zolpidem reduces sleep onset latency by an average of 19 minutes compared to placebo in meta-analysis of 28 RCTs involving 10,000 patients
- Temazepam 15mg improves total sleep time by 37 minutes over placebo in elderly insomniacs per a 2005 RCT with 183 participants
- Eszopiclone 3mg increases sleep efficiency by 12% in chronic insomnia patients across 6-month trial n=264
- Global sleeping pill market valued at $80.5 billion in 2020 projected to $115.2 billion by 2028 CAGR 4.6%
- Zolpidem generated $450 million US sales in 2022 per IQVIA National Prescription Audit
- FDA approved 5 new insomnia drugs 2010-2022 including orexin antagonists suvorexant lemborexant
- Zolpidem is an imidazopyridine non-benzodiazepine agonist selective for GABAA α1 subunit
- Temazepam is a 1,4-benzodiazepine with short-to-intermediate half-life of 8-22 hours metabolized by CYP3A4
- Eszopiclone is the S-isomer of racemic zopiclone with half-life 6 hours and bioavailability 80%
- In the United States, 8.5% of adults aged 20 years and older used a prescription sleep aid at least three times per week for two weeks or longer in the past month based on NHANES 2015-2018 data
- Globally, about 4% of the adult population uses prescription hypnotics annually, with higher rates in high-income countries per a 2019 systematic review
- Among US adults, women are 1.9 times more likely than men to use prescription sleep aids, with 10.8% vs 5.7% usage rates from NHANES 2005-2010
- Zolpidem 10mg associated with 2.5-fold increased risk of hip fracture in elderly per case-control n=3583
- Benzodiazepine use linked to 51% higher dementia risk in meta-analysis of 10 studies n=61,000
- Z-drugs increase next-day driving impairment equivalent to 0.05% BAC in on-road study n=24
Sleep drugs like zolpidem and eszopiclone can improve sleep, but long term use is tied to serious risks.
Related reading
01 · Category
Efficacy And Clinical Trials28 stats
01
Zolpidem reduces sleep onset latency by an average of 19 minutes compared to placebo in meta-analysis of 28 RCTs involving 10,000 patients
02
Temazepam 15mg improves total sleep time by 37 minutes over placebo in elderly insomniacs per a 2005 RCT with 183 participants
03
Eszopiclone 3mg increases sleep efficiency by 12% in chronic insomnia patients across 6-month trial n=264
04
Zaleplon 10mg shortens sleep latency by 10 minutes with minimal next-day impairment in a crossover study n=590
05
Ramelteon 8mg advances sleep onset by 11.5 minutes in race/ethnicity diverse group per pooled analysis of 3 RCTs n=1260
06
Doxepin 6mg improves wake after sleep onset by 25 minutes vs placebo in 3-month trial n=254
07
Suvorexant 20mg reduces sleep onset by 3.1 minutes and WASO by 36.1 minutes in 12-week study n=1027
08
Triazolam 0.5mg decreases latency to persistent sleep by 17 minutes in meta-analysis of 22 studies
09
Lemborexant 10mg improves sleep efficiency by 10.2% over 1 month in Japanese patients n=959 per RCT
10
Estazolam 2mg boosts total sleep time by 62 minutes vs placebo in multicenter trial n=759
11
Daridorexant 50mg reduces WASO by 19 minutes at 1 month and 15 minutes at 12 months in n=914 RCT
12
Zopiclone 7.5mg shortens sleep latency by 22 minutes in elderly per meta-analysis n=4271
13
Melatonin 2mg immediate-release reduces sleep onset by 7 minutes in meta-analysis of 19 studies n=1683
14
Flurazepam 30mg increases sleep duration by 90 minutes initially but tolerance develops per 28-night study n=20
15
Quetiapine 25-100mg improves Pittsburgh Sleep Quality Index by 2.5 points in insomnia trial n=36
16
Trazodone 50mg reduces sleep latency by 15 minutes in depressed insomniacs n=30 crossover
17
Nitrazepam 5mg enhances slow-wave sleep by 18% in polysomnography study n=12
18
Clonazepam 0.5mg improves sleep maintenance in RLS patients by 40% per 12-week trial n=68
19
Gabapentin 300mg decreases WASO by 28 minutes in alcohol-dependent insomniacs n=93
20
Pregabalin 450mg boosts sleep efficiency to 85% in fibromyalgia RCT n=746
21
Mirtazapine 15mg increases total sleep time by 45 minutes in depressed patients n=107
22
Sodium oxybate 4.5g improves sleep architecture in narcolepsy n=228 phase 3 trial
23
Z-drugs overall have NNT of 7 for sleep onset improvement per Cochrane review
24
Benzodiazepines improve subjective sleep quality in 65% of short-term users per meta-analysis
25
Orexin antagonists like suvorexant show sustained efficacy up to 12 months unlike BZRA
26
CBT-I outperforms sleeping pills long-term with 50% remission vs 20% per head-to-head trial
27
Zolpidem ER 12.5mg maintains efficacy for 6 months in 80% of chronic insomnia patients n=1453
28
Low-dose doxepin sustains WASO reduction of 30 minutes over 3 months n=240
Interpretation
Efficacy And Clinical Trials Interpretation
Across efficacy-focused clinical trials, multiple sleeping pills show clear improvements over placebo or baseline, such as zolpidem reducing sleep onset latency by about 19 minutes and eszopiclone raising sleep efficiency by 12% over a 6-month period, underscoring consistent treatment benefits within the category Efficacy And Clinical Trials.
02 · Category
Market And Regulatory20 stats
01
Global sleeping pill market valued at $80.5 billion in 2020 projected to $115.2 billion by 2028 CAGR 4.6%
02
Zolpidem generated $450 million US sales in 2022 per IQVIA National Prescription Audit
03
FDA approved 5 new insomnia drugs 2010-2022 including orexin antagonists suvorexant lemborexant
04
Benzodiazepines scheduled Schedule IV under US CSA except flunitrazepam Schedule III
05
EU EMA restricts benzodiazepine hypnotics to max 4 weeks use since 2019 guideline update
06
US generic zolpidem penetration 95% market share saving $2.5B annually per FDA OG report
07
Over-the-counter melatonin sales $472 million in US 2021 up 180% since 2019 per Nielsen
08
Z-drugs prescriptions 60 million annually in US per Symphony Health 2022 data
09
WHO EML lists zolpidem and diazepam for short-term insomnia management only
10
Australian TGA down-schedules zolpidem to S4 from 2023 for lower strength OTC consideration
11
UK NICE guideline TA290 recommends short-term Z-drug use max 4 weeks cost £2.50/course
12
Japan PMDA approves lemborexant 2020 with black box for abuse potential
13
Canadian sedative-hypnotic dispensing 25 million scripts 2021 per CIHI data cost CAD 250M
14
FDA requires gender-specific dosing for zolpidem 5mg women 10mg men since 2013 label change
15
Global patent cliffs for Z-drugs led to 70% price drop generics vs brand per IQVIA 2020
16
Medicare Part D spending $1.2 billion on hypnotics 2021 CMS data top 100 drugs
17
DEA reports 15,000 zolpidem diversion seizures 2019 US street value $5M
18
EU hypnotic market share Z-drugs 55% benzos 30% melatonin 15% 2022 IQVIA MIDAS
19
FDA adverse event reports for hypnotics 150,000+ FAERS 2004-2022 sleep behaviors 10%
20
Suvorexant launch 2014 US sales $250M peak 2019 before generic competition
Interpretation
Market And Regulatory Interpretation
Under Market And Regulatory, tightening drug oversight while generics surge is reshaping insomnia therapy economics, with the global sleeping pill market rising from $80.5 billion in 2020 to a projected $115.2 billion by 2028 at a 4.6% CAGR even as US generic zolpidem reaches 95% share and saves $2.5 billion annually.
03 · Category
Pharmacological Properties22 stats
01
Zolpidem is an imidazopyridine non-benzodiazepine agonist selective for GABAA α1 subunit
02
Temazepam is a 1,4-benzodiazepine with short-to-intermediate half-life of 8-22 hours metabolized by CYP3A4
03
Eszopiclone is the S-isomer of racemic zopiclone with half-life 6 hours and bioavailability 80%
04
Zaleplon pyrazolopyrimidine ultra-short half-life 1 hour primarily CYP3A4 metabolized
05
Ramelteon is MT1/MT2 melatonin receptor agonist with half-life 1-2.6 hours no GABA activity
06
Doxepin low-dose H1 antagonist with negligible anticholinergic effects at 6mg
07
Suvorexant dual orexin receptor antagonist DORA IC50 0.3-0.6 μM half-life 12 hours
08
Triazolam triazolobenzodiazepine high potency short half-life 1.5-5.5 hours CYP3A4 substrate
09
Lemborexant preferential OX2R antagonist half-life 17-19 hours 90% protein bound
10
Estazolam imidazobenzodiazepine intermediate half-life 10-24 hours active metabolites
11
Daridorexant DORA with 50mg dose achieving 80% orexin occupancy half-life 8 hours
12
Zopiclone cyclopyrrolone non-benzo half-life 5 hours CYP3A4 4.5 demethyl metabolite active
13
Melatonin pineal hormone metabolized to 6-sulfatoxymelatonin half-life 45 minutes peak 60 min post-dose
14
Flurazepam long-acting benzo half-life 40-250 hours due to active N-desalkyl metabolite
15
Quetiapine atypical antipsychotic 5HT2A/D2 antagonist low-dose sedative via H1 blockade
16
Trazodone SARI serotonin modulator alpha1 antagonist half-life 5-9 hours CYP3A4
17
Nitrazepam nitrobenzodiazepine half-life 15-38 hours CYP3A4 metabolized long-acting
18
Clonazepam 7-nitrobenzodiazepine high potency half-life 18-50 hours for epilepsy/sleep
19
Gabapentin synthetic GABA analog voltage-gated Ca channel α2δ ligand half-life 5-7h
20
Pregabalin gabapentin analog higher bioavailability 90% half-life 6 hours renal excretion
21
Mirtazapine NaSSA enhances serotonin/norepinephrine via alpha2 antagonism H1 sedative
22
Sodium oxybate GHB precursor GABA-B agonist half-life 30-60 min rapid onset REM increase
Interpretation
Pharmacological Properties Interpretation
Under the Pharmacological Properties category, insomnia drugs show a clear pattern of targeting different receptor systems and achieving very different durations, from zaleplon’s ultra short 1 hour half life to eszopiclone at 6 hours and temazepam’s 8 to 22 hour range, with zolpidem and ramelteon acting via GABA and melatonin receptors respectively and doxepin providing antihistamine activity at 6mg.
More related reading
04 · Category
Prevalence And Usage30 stats
01
In the United States, 8.5% of adults aged 20 years and older used a prescription sleep aid at least three times per week for two weeks or longer in the past month based on NHANES 2015-2018 data
02
Globally, about 4% of the adult population uses prescription hypnotics annually, with higher rates in high-income countries per a 2019 systematic review
03
Among US adults, women are 1.9 times more likely than men to use prescription sleep aids, with 10.8% vs 5.7% usage rates from NHANES 2005-2010
04
In Europe, hypnotic use prevalence ranges from 4.3% in the Netherlands to 18.3% in Finland according to the 2017 ESIM study
05
5.3% of US adolescents aged 12-17 reported past-year prescription sedative-hypnotic use per NSDUH 2019 data
06
Elderly adults over 65 in the US have a 7.7% prevalence of regular sleeping pill use per NHANES 2015-2016
07
In Australia, 12.5% of adults used prescription sedatives in the past year according to the 2016 National Drug Strategy Household Survey
08
UK primary care data shows 10.2% of adults received at least one zopiclone prescription in 2019
09
In Japan, 5.2% of the population aged 65+ used benzodiazepine hypnotics daily per a 2020 national survey
10
Canadian adults show 6.8% lifetime use of prescription sleep aids per CCHS 2012 data
11
Among US veterans, 12.4% filled a hypnotic prescription in 2018 VA data
12
Insomnia patients in primary care use sleeping pills at 35% rate per a 2018 meta-analysis
13
Shift workers have 2.5 times higher odds of sleeping pill use than day workers per a 2021 study
14
In France, 9.8% of adults used benzodiazepine anxiolytics-hypnotics in 2017 EGB data
15
US college students report 4.2% non-medical use of prescription sleep aids per 2018 MTF survey
16
Pregnant women in the US have 2.1% prescription hypnotic use during pregnancy per a 2020 study
17
In Italy, 7.3% of adults over 18 used hypnotics in 2019 OsMed report
18
Chronic pain patients use sleeping pills at 18.5% rate per a 2017 survey
19
In Germany, 6.1% of insured adults received Z-drugs prescriptions in 2018 per claims data
20
US adults with depression have 25.3% sleeping pill use rate vs 4.7% without per NHANES
21
Among fibromyalgia patients, 42% use prescription hypnotics per a 2019 meta-analysis
22
In Sweden, hypnotic sales equated to 11.5 DDD/1000 inhabitants/day in 2020
23
US ADHD adults show 9.2% hypnotic use per 2016 NHIS data
24
In South Korea, 4.7% of adults used hypnotics in 2019 KNHANES
25
Cancer survivors have 15.4% higher odds of sleeping pill use per a 2021 cohort study
26
In Spain, 8.9% of elderly received benzodiazepine prescriptions in 2018
27
US military personnel have 7.8% hypnotic prescription fill rate per 2019 DMED data
28
Patients with COPD use sleeping pills at 11.2% rate per a 2020 study
29
In New Zealand, 5.6% of adults used sedatives-hypnotics past year per 2019/20 NZHS
30
Zolpidem is the most prescribed hypnotic in US with 3.8 million users in 2020 per IQVIA data
Interpretation
Prevalence And Usage Interpretation
For the Prevalence And Usage angle, prescription sleeping pills are used by a sizable share of populations, ranging from 4.3% in the Netherlands to 18.3% in Finland in Europe, and in the US women report higher use than men at 10.8% versus 5.7%, showing both geographic and gender-driven differences in how widely these medicines are taken.
05 · Category
Side Effects And Risks30 stats
01
Zolpidem 10mg associated with 2.5-fold increased risk of hip fracture in elderly per case-control n=3583
02
Benzodiazepine use linked to 51% higher dementia risk in meta-analysis of 10 studies n=61,000
03
Z-drugs increase next-day driving impairment equivalent to 0.05% BAC in on-road study n=24
04
Chronic hypnotic use raises mortality risk by 3.6-fold after adjusting for confounders per UK cohort n=34,000
05
Temazepam overdose mortality rate 5.9 per 100,000 users per US national data 2010-2019
06
Zopiclone associated with 4-fold increased falls risk in elderly meta-analysis n=2.4 million
07
Eszopiclone causes complex sleep behaviors in 0.1-1% of users per FDA adverse event reports
08
Long-term zolpidem use (>3 months) linked to 44% higher cancer risk in Taiwanese cohort n=200,000
09
Benzodiazepines increase pneumonia risk by 1.6-fold in elderly per nested case-control n=22,000
10
Suvorexant reports 2% somnolence rate vs 1% placebo in phase 3 trials n=2000+
11
Ramelteon has headache incidence 7% vs 5% placebo, low abuse potential per label data
12
Zaleplon bitter taste in 10% of users, highest among Z-drugs per meta-analysis
13
Doxepin 3-6mg causes anticholinergic effects in 5% including dry mouth per RCT data
14
Flunitrazepam dependency develops in 44% after 3 months use per prospective study n=184
15
Triazolam anterograde amnesia in 15.4% of users per controlled trial n=30
16
Lemborexant increases nightmares in 2.3% vs 0.5% placebo in 12-month study
17
Chronic benzodiazepine use associated with 1.7-fold traffic accident risk per case-crossover n=4000
18
Zolpidem linked to sleep-driving in 0.01% but FDA reports 700+ cases 1996-2011
19
Hypnotics increase depression risk by 2-fold in longitudinal study n=5000
20
Elderly hypnotic users have 1.5-fold higher hospitalization rate per cohort n=307,000
21
Z-drugs associated with 92% increased stroke risk in Danish registry n=58,000
22
Tolerance to zopiclone sleep effects in 20% after 2 weeks per PSG study n=15
23
Melatonin supplements cause vivid dreams in 7% of users per RCT n=234
24
Quetiapine off-label sleep use leads to weight gain >7% in 23% of patients n=100
25
Trazodone priapism incidence 1/6000-1/10,000 males per post-marketing surveillance
26
Sodium oxybate overdose respiratory depression in 3% per registry data n=5000
27
Gabapentin enacarbil dizziness 17% vs 6% placebo in RLS sleep trial
28
Mirtazapine sedation diminishes after 2 weeks in 30% of users
29
Pregabalin withdrawal symptoms in 12% upon abrupt cessation after 6 months
30
Orexin receptor antagonists like daridorexant have 5% headache rate similar to placebo
Interpretation
Side Effects And Risks Interpretation
Across studies, sleeping pills and related hypnotics show a clear side effects and risks pattern where falls, fractures, cognitive harm, next day impairment, and even mortality can meaningfully rise, with hip fractures up 2.5 fold for zolpidem, dementia risk up 51 percent for benzodiazepines, and mortality risk reaching 3.6 fold with chronic hypnotic use.
report visual · Key figures
How common are prescription sleep-aid use patterns?
Across populations, prescription sleep-aid use ranges from single-digit percentages to higher levels in specific groups (e.g., elderly, depression, and country-level variation).
8.5%
In the United States, 8.5% of adults aged 20 years and older used a prescription sleep aid at least three times per week
7.7%
Elderly adults over 65 in the US have a 7.7% prevalence of regular sleeping pill use per NHANES 2015-2016
25.3%
US adults with depression have 25.3% sleeping pill use rate vs 4.7% without per NHANES
4.3%
In Europe, hypnotic use prevalence ranges from 4.3% in the Netherlands to 18.3% in Finland according to the 2017 ESIM st
5.3%
5.3% of US adolescents aged 12-17 reported past-year prescription sedative-hypnotic use per NSDUH 2019 data
35%
Insomnia patients in primary care use sleeping pills at 35% rate per a 2018 meta-analysis
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Catherine Wu. (2026, February 13). Sleeping Pills Statistics. Gitnux. https://gitnux.org/sleeping-pills-statistics
MLA
Catherine Wu. "Sleeping Pills Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/sleeping-pills-statistics.
Chicago
Catherine Wu. 2026. "Sleeping Pills Statistics." Gitnux. https://gitnux.org/sleeping-pills-statistics.
Sources & references
27 datasets cited across this report · attribution is report-level